low - Clinical trial timelines and FDA processes are largely insulated from GDP fluctuations. Patient enrollment in rare disease trials driven by medical need rather than economic conditions. However, severe recessions can impact biotech financing availability and M&A activity, affecting capital raising ability and partnership valuations.

High sensitivity to interest rates through multiple channels: (1) Valuation impact - biotech DCF models heavily weight distant cash flows, making valuations compress significantly when discount rates rise (10-year Treasury used as risk-free rate baseline); (2) Financing costs - higher rates increase dilution required in equity raises and make convertible debt more expensive; (3) Risk appetite - rising rates shift institutional capital away from speculative growth/biotech toward safer yield alternatives. The -70.6% one-year return correlates with 2024-2025 rate environment.

growth - High-risk, high-reward biotech investors seeking 3-10x returns from clinical trial success and FDA approvals. Attracts specialized healthcare hedge funds, biotech-focused venture investors, and retail speculators willing to accept binary outcomes. Not suitable for value or income investors given negative cash flows, no dividends, and speculative nature. Recent -70.6% one-year return reflects typical volatility profile.